Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

CD38 ectonucleotidase inhibition (a brake on NAD+ consumption)

CD38 Ecto-Enzyme Inhibition · Metabolic sensing, autophagy and longevity

Binds and inhibits CD38, a glycohydrolase highly expressed on the surface of macrophages and endothelial cells, largely cutting off its pathological breakdown of NAD+ both inside and outside cells.

Why it matters: The sharp rise in CD38 expression with aging is a key culprit in tissue NAD+ depletion. Inhibiting CD38 is like patching the hole in a leaking bucket, which gives it a strong synergistic effect with NAD+ precursor supplementation.

Molecular targets: CD38 catalytic domain, NAD+-degrading hydrolase, Inhibition of cADPR synthesis

Supplements acting on this mechanism (ranked by strength and evidence)

Apigenin

★☆☆☆☆Mechanism evidence: grade D

In enzyme assays, apigenin inhibited CD38 with an IC50 of about 10.3 μmol/L, and liver NAD+ rose in treated mice. However, this in-vitro inhibitory concentration is far above the plasma levels measured in human dietary studies, and whether 50–200 mg of pure apigenin can reach an effective free exposure in humans has not been confirmed.

Open in the interactive app ›